Medscape

FDA Approves HIV-1 Treatment Ibalizumab for 30-Second IV Push

The Food and Drug Administration (FDA) has approved the HIV-1 medication ibalizumab-uiyk (Trogarzo, Theratechnologies Inc) for administration by intravenous push. Ibalizumab-uiyk, a long-acting ...
streetinsider

Theratechnologies (THTX) Trogarzo Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), ...
Yahoo Finance

Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

MONTREAL, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and ...
Monthly Prescribing Reference

Trogarzo Label Updated With 90-Second IV Push Loading Dose

The new approval allows for the 2000mg loading dose to be administered as an IV push rather than a 30-minute IV infusion. The prescribing information for Trogarzo ® (ibalizumab-uiyk) has been updated ...
Yahoo Finance

Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population

MONTREAL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and ...
Nasdaq

Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...